Total Utang marang Modal: Cyclacel (CYCC)

Cyclacel Pharmaceuticals (CYCC) develops cell cycle regulation agents for the therapy of solid tumors in the UK and the US. This market valuation chart reflects a debt load of 0.00, which is critical amid cost optimization and anticipation of trial data for the fadraciclib inhibitor. The business operations are protected by the humanitarian status of biomedicine, minimizing the impact of external political shocks.

This metric measures the business's degree of dependence on borrowed funds by comparing total liabilities to equity to assess financial stability. By analyzing the total debt-to-equity ratio, an investor can evaluate the extent to which the capital-intensive cancer drug development and patent portfolio of Cyclacel Pharmaceuticals (CYCC) rely on leverage or internal resources.